Ex-Novartis John Tsai Takes The Reins At Cardiovascular-Focused Forcefield Therapeutics
Heart Attack Damage Prevented In Mouse Studies
The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.
